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Abstract
Background: Eosinophilic esophagitis (EoE) is a chronic antigen-mediated clinico-
pathologic disease of the esophagus characterized by an eosinophil-predominant
inflammatory infiltrate. A clinical hallmark is extensive tissue remodeling includ-
ing basal zone hyperplasia, fibrosis, and angiogenesis. However, the cellular
mechanisms responsible for these processes are not fully defined. We hypothesized
that targeting granulocyte-macrophage colony-stimulating factor (GM-CSF; an
agonist cytokine linked with eosinophil survival and activation) would be protec-
tive in a preclinical model of EoE.
Methods: Eosinophilic esophagitis-like esophageal inflammation was induced in
the L2-IL5OXA EoE mouse model, and GM-CSF production was assessed by
mRNA and protein analyses. Granulocyte-macrophage colony-stimulating factor-
receptor-alpha expression patterns were examined by flow cytometric and
immunofluorescence analysis. L2-IL5OXA EoE mice were treated with anti-GM-
CSF neutralizing antibody or isotype control and assessed for histopathological
indices of eosinophilia, epithelial hyperplasia, and angiogenesis by immunohisto-
chemistry and RT-PCR.
Results: Significantly increased levels of esophageal GM-CSF expression was
detected in the L2-IL5OXA mouse EoE model during active inflammation. Granu-
locyte-macrophage colony-stimulating factor-receptor-alpha was predominantly
expressed on esophageal eosinophils during EoE, in addition to select cells within
the lamina propria. Anti-GM-CSF neutralization in L2-IL5OXA EoE mice
resulted in a significant diminution of epithelial eosinophilia in addition to basal
cell hyperplasia and vascular remodeling. This treatment response was indepen-
dent of effects on esophageal eosinophil maturation or activation.
Conclusion: Granulocyte-macrophage colony-stimulating factor is a potential
therapeutic target to reduce esophageal eosinophilia and remodeling.
Eosinophilic esophagitis (EoE) is a chronic antigen-
mediated clinicopathologic disease of the esophagus. A
histologic and diagnostic hallmark of EoE is the accumu-
lation of an eosinophil-predominant inflammatory infil-
trate within esophageal mucosa. Eosinophilic esophagitis,
like other atopic diseases, is growing in incidence and
prevalence (1, 2). Existing medical treatments of EoE are
limited to topical corticosteroids, diet restrictions, and
esophageal dilation. However, these approaches have been
associated with side-effects and negative impact on quality
of life (3, 4). Moreover, the recent use of available bio-
logics targeting eosinophils has not achieved clinical effi-
cacy, thus leading to the need for identification of new
therapeutic targets (5, 6).
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Granulocyte-macrophage colony-stimulating factor (GM-
CSF) was first defined because of its ability to generate colo-
nies of mature granulocytes and macrophages from myeloid
progenitors in vitro and is now known as a key mediator of
eosinophilopoiesis. Granulocyte-macrophage colony-stimulat-
ing factor is induced by bacterial endotoxins and certain
cytokines in many cell types including leukocytes (i.e. macro-
phage, mast cells, and T cells) and nonleukocytes (i.e. fibrob-
lasts, endothelial, mesothelial, and epithelial cells) with
actions on cells expressing the GM-CSF-Ra such as eosino-
phils, basophils, DC-like cells, monocytes/macrophages, and
neutrophils. Besides eosinophil progenitor proliferation and
maturation, GM-CSF is now recognized to have a range of
functions on mature eosinophils including dose-dependent
eosinophil priming, migration, and degranulation (7–9). In
addition, GM-CSF may also induce angiogenesis in multiple
tissues by activating both proliferation and migration of
endothelial cells (10–13).
We hypothesized that targeting GM-CSF would be protec-
tive in a preclinical model of EoE. The purpose of this study
was to evaluate the potential use of an anti-GM-CSF anti-
body treatment on the inflammatory patterns related to eso-
phageal eosinophilia, epithelial basal zone hyperplasia, and
angiogenesis as a measure of postinflammatory epithelial
remodeling. Using our previously described L2-IL5OXA
mouse model of EoE (14), we show that treatment with an
anti-mouse GM-CSF monoclonal antibody significantly
reduced epithelial eosinophilia, basal cell hyperplasia, and
angiogenesis. The data support the importance of GM-CSF
in the accumulation of eosinophils in EoE, suggesting it as a
potential target for further clinical investigation.
Materials and methods
Mice
All studies were performed with male or female L2-IL5 mice
on a C57BL/6J background generated as previously described
(14). Animals were maintained in micro-isolator cages housed
in a specific-pathogen-free facility at the University of Color-
ado. Age- and sex-matched L2-IL5 mice were used as con-
trols. Studies involving animals were performed in
accordance with National Institutes of Health, University of
Colorado IACUC guidelines.
Induction of experimental EoE in L2-IL5OXA mice using 4-
ethoxymethylene-2-phenyl-2-oxazolin-5-one (oxazolone or
OXA)
Induction of esophageal eosinophilic inflammation in mice
(L2-IL5OXA EoE) was established using a 4-ethoxymethy-
lene-2-phenyl-2-oxazolin-5-one (oxazolone or OXA) (Sigma,
St Louis, MO, USA) contact hypersensitivity protocol as
previously described (Fig. 3A) (14). Briefly, on day 0 of the
protocol, anesthetized mice were shaved on the abdomen
and oxazolone was applied to the skin surface (150 ll of a
3% (w/v) solution of OXA in 4 : 1 acetone-olive oil vehicle)
to initiate the sensitization phase of the protocol (15). On
days 5, 8, and 12, mice were challenged by an intra-esopha-
geal gavage of 100 ll of a 1% (w/v) OXA in 30% ethanol/
olive oil vehicle. Vehicle control L2-IL5 mice were sensitized
as above and challenged with vehicle alone. All mice were
assessed 24 h following the last OXA challenge (protocol
day 13).
In some studies, a GM-CSF depleting antibody was
administered to mice. These studies were completed using a
monoclonal rat IgG2a antibody specific for murine GM-CSF
(Clone # MP122E9) or monoclonal rat IgG2a isotype control
antibody (Clone # 54447; R&D Systems, Minneapolis, MN,
USA). Experimental animals were injected with four
intraperitoneal (i.p.) doses of anti-GM-CSF antibody
(0.5 mg/mouse) or IgG2a isotype control on days 5, 8, 10,
and 12 during experimental esophagitis (Fig. 3A). Mice were
killed 24 h following final treatment (day 13).
Tissue processing and immunohistochemical assessment of
tissues
Whole-length esophageal tissues were removed and fixed
with 10% neutral-buffered formalin, processed, paraffin-
embedded, and cut into 5-lm sections. Sections were
stained with hematoxylin and eosin (H&E) (Sigma) or sub-
jected to immunohistochemistry for eosinophil major basic
protein-1 (MBP-1; Clone MT-14.7) (Lee Labs, Mayo
Clinic, AZ, USA), Ki67 (Dako, Carpinteria, CA, USA) to
assess cell proliferation, both as previously described (14)
or CD31 (PECAM) (Abcam, Cambridge, MA, USA).
MBP-1 immuno-positive cells were visualized with perma-
nent red chemotrope, Ki67 immuno-positive cells were
visualized with DAB chemotrope (Dako), and the slides
were counterstained with Methyl Green (Vector Laborato-
ries, Burlingame, CA, USA). CD31 (PECAM) immuno-
positive cells were visualized with a fluorescently tagged
Alexa Fluor 488 antibody (Invitrogen, Grand Island, NY,
USA), and slides were counterstained with DAPi (Invitro-
gen). Control sections replaced the primary antibody in
each case with a rat IgG isotype control antibody (Vector
Laboratories). Quantification of either MBP-1 or Ki67
immuno-positive cells was determined by gathering the
numerical averages of nine nonoverlapping high-power
fields (0.26 mm2) per esophagus (three distal, three mid,
and three proximal). Mean vessel density was determined
as previously described (16) from an average of nine
nonoverlapping high-power fields per esophagus (three dis-
tal, three mid, and three proximal). Numbers are presented
as a mean  SEM.
Esophageal leukocyte isolation, quantification, and flow
cytometric analysis
Esophageal leukocytes were isolated as previously described
(14). Briefly, esophagi were resected, cut longitudinally,
washed in PBS, and then digested with collagenase (Sigma)
as previously described for other intestinal tissues (17). Cell
counts and viability of recovered leukocytes were determined
with a hemocytometer and trypan blue exclusion.
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Single-cell suspensions were blocked using 1 lg/ll of Fc
blocker (CD16/32; eBiosciences, San Diego, CA, USA).
Cells were then stained for 2 h at 4° with cell type-specific
antibodies. Antibodies used for the staining of specific cell
surface markers include GM-CSF-Ra (698423), Ly6G
(1A8), Ly6C (AL-21), IL-5Ra (T21), CCR3 (83103), SiglecF
(E50-2440) (BD Biosciences, San Jose, CA, USA); NK1.1
(PK136), MHC-II (M5/114.15.2), FceR1a (MAR-1),
CD200R3 (Ba13), CD80 (16-10A1) (BioLegend, San Diego,
CA, USA); and CD11b (M1/70), CD34 (RAM34), CD45
(30-f11), CD49b (DX5), CD3e (145-2C11), CD19 (1D3),
EPCAM (G8.8), CD69 (H1.2F3) (eBiosciences). Viable cells
were determined with the use of Live/Dead AquaVi staining
(Invitrogen). Flow cytometric analysis was performed using
a BD FACSCantoTM II (BD Biosciences). Data files were
further analyzed using FLOWJO software (Tree Star Inc,
Ashland, OR, USA).
Cell culture
EPC2-hTERT immortalized human esophageal epithelial
cells were cultured as previously described (18). EPC2-
hTERT cells were seeded at 60 000 cells per well of a 24-well
plate and 24 h after plating cells were switched to high-cal-
cium (1.8 mM) medium for a further 48 h. Cells were then
washed and treated for 24 h with varying concentrations of
rhGM-CSF (R&D Systems). Cells were harvested for mRNA
analysis using RLT buffer from Qiagen RNeasy kits (Qiagen,
Valencia, CA, USA).
RNA isolation and real-time RT-PCR
Total RNA was prepared from whole distal esophageal tis-
sues with RNeasy Mini Kits (Qiagen) and handheld labora-
tory homogenizer (PRO Scientific, Oxford, CT, USA). First-
strand cDNA synthesis was performed from 500 ng of total
RNA using the High Capacity cDNA archive kit (Applied
BioSystems, Foster City, CA, USA). Transcript expression
was assessed using Taqman Gene Expression Assays Taqman
probes (Applied Biosystems). rtRT-PCR was performed with
ABsoluteTM Blue QPCR ROX Mix (Thermo Scientific, Sur-
rey, UK). Thermocycling and analysis were performed with
ABI-7300 System and software (Applied BioSystems, Foster
City, CA, USA). Data were normalized to 18S expression
and calculated as RQ (Relative Quantity; 2DDCt , where Ct is
cycle threshold) for each sample.
GM-CSF protein assessment of esophageal tissue
Esophagi were resected, cut longitudinally to expose the
luminal surface, washed in PBS, snap-frozen, and stored at
80°C prior to use. Tissues were homogenized in MSD lysis
buffer containing Roche complete mini protease inhibitor
cocktail (Sigma) and assessed for GM-CSF protein content
using a mouse GM-CSF-specific Mesoscale Assay (as per the
manufacturer’s instructions) [Meso Scale Diagnostics (MSD),
Rockville, MD, USA] or total protein content using BCA
Assay (Thermo Fisher, Waltham, MA, USA).
Statistical analysis
Statistical analyses of data outcomes were performed by Stu-
dent’s t-test. Data are expressed as means  SEM. A P-value
of ≤0.05 was considered as statistical significance although in
some cases, higher levels of significance are noted and
described in the figure legends where applicable. *P ≤ 0.05,
**P ≤ 0.01, ***P ≤ 0.001.
Results
GM-CSF expression is increased in esophageal eosinophilia
To understand the potential impact of GM-CSF on esopha-
geal eosinophilia, we performed three sets of experiments (1).
We first tested to see whether GM-CSF expression was ele-
vated in the esophagus linked with the eosinophil-predomi-
nant inflammation occurring in the L2-IL5OXA mouse model
of EoE. After 8 days, we examined both mRNA and protein
expression in the esophageal tissue and found both to be sig-
nificantly increased (mRNA: 1.3  0.3 vs 9.0  1.9, P ≤ 0.05;
Protein: 128  35 vs 556  179 pg/ml, P ≤ 0.05, OXA vs
Veh-Ctrl) (Fig. 1A,B) (2). We tested whether GM-CSF would
stimulate esophageal epithelial cells to release pro-allergic
molecules given that epithelial cells exposed to GM-CSF are
associated with perpetuation of atopic inflammatory condi-
tions such as atopic dermatitis (19, 20). Our results showed
that exposure of the human esophageal epithelial cells to
rhGM-CSF induced the concentration-dependent production
of GM-CSF in vitro (1.97  0.47-fold increase, anti-GM-CSF
vs IgG-Ctrl, P ≤ 0.05) (Fig. 1C). (3) We went on to examine
expression of the GM-CSF-Ra in various myeloid-type leuko-
cyte populations present during active inflammation in L2-
IL5OXA mouse EoE. Here, we found by flow cytometry that
GM-CSF-Ra was expressed at highest per-cell concentration
on neutrophils and MHCII+ cells, and to a lesser degree on
eosinophils and basophils (Fig. 2A,Bi). MHCII+ cells were
further assessed and defined into three populations stratified
as macrophage (live, single cells, CD45+, SiglecF, Ly6C,
MHCII+), monocytes (live, single cells, CD45+, SiglecF,
MHCII, Ly6C+), and dendritic cells (live, single cells,
CD45+, SiglecF, CD11c+, MHCII+) and presented as
absolute cell numbers, with macrophage being the most abun-
dant of these three MHCII bearing populations (Fig. 2Bii).
Assessment of cell frequency in mouse esophagi found that
neutrophils were rare compared to other leukocytes such as
eosinophils (Fig. 2Bii). Immunofluorescent assessment of
GM-CSF-Ra and SiglecF revealed costaining for both to a
significant degree compared to cells of the lamina propria that
were positive for GM-CSF-Ra alone (Fig. 2Ci–iii).
Anti-GM-CSF antibody treatment attenuates esophageal
epithelial eosinophilia
We tested the hypothesis that depletion of GM-CSF protein
by antibodies would reduce the esophageal eosinophilia in
L2-IL5OXA EoE mice. Experimental groups of animals were
given anti-GM-CSF antibody (via intraperitoneal injection,
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Figure 1 Molecular analysis of GM-CSF expression in the L2-
IL5OXA model of eosinophilic esophagitis (EoE). (A) mRNA and (B)
protein expression in control (L2-IL5VEH/WTOXA) and EoE (L2-
IL5OXA) mouse esophagi. (C) mRNA expression of GM-CSF
transcript by esophageal epithelial cells following in vitro stimula-
tion with a dose range of rhGM-CSF. Statistical significance was
assessed using the Students’ t-test, *P < 0.05. Data are expressed
as means  SEM.
Figure 2 Eosinophils predominantly express GM-CSF-Ra in L2-
IL5OXA mice. (A) Histographical representation of GM-CSF-Ra
expression levels on cell populations from the esophagus of L2-
IL5OXA eosinophilic esophagitis (EoE) mice by flow cytometric analy-
sis. (Bi) Bar graph representation of mean fluorescence intensities
(MFIs) for GM-CSF-Ra on selected cell populations of the esopha-
gus of L2-IL5OXA EoE mice. (Bii) Absolute abundance of selected
leukocyte populations per esophagus of L2-IL5OXA EoE mice. Holm–
Sidak’s correction for multiple-comparisons one-way ANOVA vs to
control. *P < 0.05, **P < 0.01, ***P < 0.001. (C) Immunofluores-
cence examination of esophageal tissue sections from L2-IL5OXA
EoE mice for (Ci) GM-CSF-Ra (green), (Cii) SiglecF (magenta), and
(Ciii) double-positive (yellow) cells. Arrowhead indicates lamina pro-
pria cells positive for GM-CSF-Ra alone. Arrow indicates double-
positive cells.
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control animals received isotype-matched serum
immunoglobulin) beginning day 5, the day of the first intra-
esophageal challenge and on days 8, 10, and 12 after induc-
tion of esophagitis (Fig. 3A). Anti-GM-CSF treatment lead
to a significant decrease in epithelial eosinophilia as measured
by counting intact eosinophils and assessing eosinophil MBP-
1 staining compared to anti-IgG2a isotype control-treated
L2-IL5OXA EoE mice (Fig. 3B,Ci). The pattern of inhibition
appeared to be most notable in the distal and middle esopha-
gus. In addition, eosinophilia in the lamina propria was also
reduced significantly (Fig. 3Cii) but no effect was observed
on eosinophilia in the muscle layers (Fig. 3Ciii).
To elucidate whether these effects were locally restricted
within the esophagus or were as a result of effects on
eosinophil development and circulation, peripheral eosinophils
were assessed from the spleen and bone marrow compartments
by flow cytometry (Live, SSC-hi, CD45+, Ly6G, SiglecF+).
No significant change was detected when quantifying periph-
eral eosinophilia (Bone Marrow: 3 9 106 vs 2.6 9 106,
P = 0.46; Spleen: 13.7 9 106 vs 12.7 9 106, P = 0.69; Anti-
GM-CSF-L2-IL5OXA vs IgG-Ctrl-L2-IL5OXA). Importantly,
mice treated with anti-GM-CSF did not experience any effect
on the overexpression of IL-5 in the esophagus (1.4  0.4 vs
0.98  0.1, P = 0.3; anti-GM-CSF-L2-IL5OXA vs IgG-Ctrl-
L2-IL5OXA). Thus, there was no observable effect on the base-
line model system in the context of treatment and findings
reported here were as a direct result of anti-GM-CSF on the
inflammatory and remodeling consequences.
Figure 3 GM-CSF blockade limits epithelial eosinophilia in L2-
IL5OXA mice. Schematic of the induction of mouse eosinophilic
esophagitis (EoE) (L2-IL5OXA) and the anti-GM-CSF treatment regi-
men used in these studies. Anti-GM-CSF antibody: Clone
MP122E9, R&D Systems MAB415. 0.5 mg/mouse per dose. p.c.
percutaneous, that is, intra-esophageal, i.p. intraperitoneal adminis-
tration. (B) Representative MBP photomicrographs from the distal
esophagus of control anti-IgG2A-treated L2-IL5
OXA EoE mice and
anti-GM-CSF-treated L2-IL5OXA EoE mice. (C) Eosinophils per high-
powered field were quantified in each tissue compartment (epithe-
lial, lamina propria, muscle) and esophageal site (proximal, middle,
distal) and compared between L2-IL5OXA EoE mice that underwent
anti-GM-CSF to those that underwent anti-IgG2A control antibody
treatment. Statistical significance was assessed using the Stu-
dents’ t-test, *P < 0.05. Data are expressed as means  SEM.
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Anti-GM-CSF antibody treatment does not affect esophageal
eosinophil maturation, activation markers, or eosinophil
chemoattractant expression
Given its role as an eosinophilopoietin, we examined
whether depletion of GM-CSF during esophagitis would
affect the maturation status of eosinophils in mice treated
with anti-GM-CSF when compared to those treated with
anti-IgG2a control (Fig. 4). We identified esophageal
eosinophils by flow cytometry as FSChi, SSChi, live, single
cells, CD45+, and SiglecF+ (Fig. 4A). We then examined
these cells for the level of expression of various maturation
and activation markers. We found no effect of anti-GM-
CSF on the expression levels of any of these selected mark-
ers (Fig. 4B). We also examined whether anti-GM-CSF
would affect esophageal tissue expression of eosinophil
chemokines CCL11 and CCL24 (eotaxins 1 and 2) and
found no effect (Fig. 4C).
Figure 4 GM-CSF treatment does not affect eosinophil activation
or maturation in L2-IL5OXA mice. (A) Flow cytometric identification
of esophageal eosinophils and (B) analysis of maturation and activa-
tion markers on eosinophils in L2-IL5OXA eosinophilic esophagitis
(EoE) mouse esophagi comparing anti-GM-CSF antibody-treated to
IgG2A isotype control antibody-treated mice. (C) Analysis of distal
whole esophageal total mRNA for levels of the transcripts for
CCL11 and CCL24 in L2-IL5OXA EoE mice comparing anti-GM-CSF
to anti-IgG2A control antibody-treated groups. No statistically signifi-
cant differences were observed using Students’ t-test.
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Anti-GM-CSF antibody treatment resolves basal cell
hyperplasia and epithelial remodeling
Next, the effects of anti-GM-CSF depletion on epithelial
remodeling and basal cell hyperplasia were assessed (Fig. 5).
A substantial improvement in basal cell hyperplasia and the
homeostatic localization of proliferative cells as demarcated
by Ki67 immunohistochemistry was observed following treat-
ment (Fig. 5A). When enumerated, the most significant
improvement was observed in the proximal and distal esoph-
agus (Fig. 5B).
Anti-GM-CSF antibody treatment decreases blood vessel
density and angiogenic factor production
Finally, the role of GM-CSF in esophageal vascular remodel-
ing in the context of eosinophilic inflammation was examined
(Fig. 6). PECAM (CD31)-positive vessel density was enumer-
ated, and it was found that anti-GM-CSF treatment resulted
in a lower vessel density compared to IgG control-treated
L2-IL5OXA animals (Fig. 6A,B). When the expression of
angiogenic stimulating factors including angiogenin and
angiopoietins 1 and 2 was assessed, it was also determined
that anti-GM-CSF treatment led to significantly reduced
levels of these growth factors (Fig. 6C–E). In addition, GM-
CSF blockade significantly decreased esophageal levels of
endothelial markers PECAM and von Wilebrand Factor
(vWF) compared to IgG-treated controls (Fig. 6F,G).
Interestingly, no difference in the expression levels of the
activation markers CDH5, VCAM, or VEGF-A was detected
(Fig. 6H–J). We also assessed each of these molecular mark-
ers in the context of uninflamed L2-IL5VEH esophagi and
found a significant decrease in selected markers (VWF: 40%
decrease 4%, P < 0.05, ANG2: 60% decrease 11%,
P < 0.05, PECAM: 62% decrease 16%, P < 0.05) in the
esophagi treated with anti-GM-CSF antibody when com-
pared to L2-IL5VEH IgG control-treated animals. However,
importantly, this did not lead to a decrease in the number of
PECAM+ blood vessels in anti-GM-CSF antibody-treated
uninflamed L2-IL5VEH mice (0.08  0.03 vs 0.07  0.02,
P = 0.75; anti-GM-CSF-L2-IL5VEH vs IgG-Ctrl-L2-IL5VEH).
Thus, therapeutic intervention with anti-GM-CSF limits
epithelial remodeling and angiogenic activation during active
disease in the L2-IL5OXA model of EoE.
Discussion
In our studies, we directly examined the physiologic impact
of targeting GM-CSF, a crucial eosinophilopoietin in
the pathogenesis of esophageal eosinophilia and epithelial
remodeling in the L2-IL5OXA mouse model of EoE. We
demonstrated that GM-CSF expression is increased in the
L2-IL5OXA mice and that a targeted antibody-mediated
GM-CSF blockade results in a significant decrease in epithe-
lial eosinophilia, decreased epithelial basal cell hyperplasia,
and decreased angiogenesis, resulting in overall attenuation
Figure 5 Anti-GM-CSF limits esophageal epithelial basal cell hyper-
plasia and proliferation in L2-IL5OXA mice. (A) Representative Ki67
photomicrographs from the distal esophagus of control anti-IgG-
treated L2-IL5OXA eosinophilic esophagitis (EoE) mice and anti-GM-
CSF-treated L2-IL5OXA EoE mice. (B) Total numbers of Ki67-positive
proliferating epithelial cells per high-powered field were quantified
and compared between L2-IL5OXA EoE mice that underwent
anti-GM-CSF to those that underwent anti-IgG control antibody
treatment. Statistical significance was assessed using the
Students’ t-test, *P < 0.05. Data are expressed as means  SEM.
Figure 6 GM-CSF blockade attenuated angiogenesis and vascular
remodeling in L2-IL5OXA mice. (A) Representative PECAM photomi-
crographs from the distal esophagus of anti-IgG-treated L2-IL5OXA
eosinophilic esophagitis (EoE) mice and anti-GM-CSF-treated L2-
IL5OXA EoE mice. (B) Average density of PECAM-positive vessels
per mm2 was quantified and compared between L2-IL5OXA EoE
mice that underwent anti-GM-CSF to those that underwent anti-
IgG control antibody treatment. Analysis of distal whole esophageal
total mRNA for levels of the transcripts for (C) ANG, (D) ANGPT1,
(E) ANGPT2, (F) PECAM, (G) vWF, (H) CDH5, (I) VEGF-A, and (J)
VCAM in L2-IL5OXA EoE mice comparing anti-GM-CSF to anti-IgG2A
control antibody-treated groups. Statistical significance was
assessed using the Students’ t-test *P < 0.05. Data are expressed
as means  SEM.
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of EoE-like disease in this delayed-type hypersensitivity
model. Collectively, these studies demonstrate that targeting
GM-CSF plays an important role in reducing eosinophil
numbers and remodeling in a mouse model of EoE.
Despite the fact that clinical intervention studies have
shown that inhibition of another eosinophilopoietin inter-
leukin (IL)-5 significantly reduced eosinophilia (21–26), these
studies failed to demonstrate clinical benefit (5, 6). We sought
to understand the potential role of another therapeutic tar-
get, GM-CSF, to address the need for alternative treatment
options. Previous studies have demonstrated that targeting
GM-CSF influences leukemogenesis in an in vitro model of
chronic myelomonocytic leukemia (27), inflammatory
responses in experimental arthritis (28, 29), reduced tissue
macrophage in rat model of myocardial infarction (30), and
reduced Amyloid b1-42 and microglial activity in a mouse
model of Alzheimer’s disease (31). Two studies have also
directly examined the influence of anti-GM-CSF therapy on
bronchoalveolar lavage fluid eosinophilia in mouse models of
allergic airway inflammation (32, 33), and an ongoing trial is
examining anti-GM-CSF antibodies’ role in subjects with
asthma. Moreover, two human clinical trials are ongoing,
studying the effects of anti-GM-CSF in rheumatoid arthritis
(34, 35). While many preclinical and clinical studies targeting
GM-CSF for inflammatory diseases are ongoing, the role of
GM-CSF and the impact of anti-GM-CSF therapies in EoE
have not been assessed to date.
Here, we provide evidence for the increased presence of
GM-CSF and for its role in esophageal epithelial eosinophilia
in the L2-IL5OXA mouse model of EoE. Previous studies
using eotaxin/ genetically targeted mice in a mouse model
of EoE still accumulated esophageal eosinophils, implicating
additional chemotactic axes in esophageal epithelial recruit-
ment (23). We show that reduced epithelial eosinophilia is
not a result of effects of anti-GM-CSF treatment on esopha-
geal eosinophilic chemokines eotaxin-1 or -2 or on eosinophil
development and circulation. Granulocyte-macrophage col-
ony-stimulating factor acts on mature eosinophils to elicit
priming, migration, and degranulation (7–9). Here, we show
no effect of anti-GM-CSF therapy on esophageal eosinophil
expression of maturation or activation markers. These find-
ings suggest that decreased esophageal epithelial eosinophilia
in the L2-IL5OXA EoE mouse model may be acting through
local effects of GM-CSF within the esophagus, possibly
limiting intra-epithelial eosinophil survival or indirectly via
antigen-presenting cells. Our data would also suggest that
GM-CSF has a direct role of vascular activation and remod-
eling, which may also limit eosinophil trafficking to the
inflamed esophagus. Previous literature supports the effects
of GM-CSF on cells of the mature myeloid lineage including
PMNs (polymorphonuclear leukocytes), monocytes/macro-
phage, basophils, and eosinophils (36). Here, we confirm the
expression of esophageal GM-CSF-receptor-alpha in the L2-
IL5OXA mouse EoE model is primarily on eosinophils, and to
a lesser extent on basophil- and MHCII-positive cells. Future
studies need to examine the role of GM-CSF on all cells
involved in EoE pathogenesis in order to elucidate why anti-
GM-CSF mostly affected epithelial eosinophilia and to model
what effect an anti-GM-CSF therapy would have on chronic
disease and/or esophageal remodeling.
Targeting eosinophilopoiesis (via IL-5 blockade) in both
mouse models and in clinical trials have failed to demon-
strate therapeutic efficacy in EoE (5, 6). Granulocyte-macro-
phage colony-stimulating factor along with IL-5 and IL-3 are
a triad of important, although thought to be potentially
redundant, cytokines associated with eosinophil development
in the bone marrow. This study demonstrates for the first
time that anti-GM-CSF attenuates esophageal epithelial
eosinophilia, epithelial, and vascular remodeling and impli-
cates GM-CSF signaling as a potential therapeutic target that
warrants further investigation in EoE.
As with any mouse model, translation to clinical relevance
is critical. However, this study suggests GM-CSF is a poten-
tial target that may offer new opportunities for the clinical
management of patients with EoE.
One of the limitations of our study is the dosing regimen
used. More frequent administrations may have been more
completely effective. Equally, mice were treated by intraperi-
toneal administration of antibody. Current therapeutic
approach in patients with EoE selectively targets the esopha-
gus with orally administered steroids. Future studies should
consider a mechanism to directly target the esophagus with
antibody, or indeed with other molecular-inhibiting method-
ologies. The focus of the current study was the net effect on
eosinophils, the effects on maturation and survival, specifi-
cally in the esophagus with or without anti-GM-CSF
treatment. Other physiological effects may be altered via
GM-CSF suppression. These include effects on antigen-
presenting cell(s) as well as the effects of GM-CSF on the
epithelium in EoE. What is known is that GM-CSF is over-
produced by keratinocytes in atopic dermatitis, and this has
implications for dendritic cell activation (20). Our studies
implicate anti-GM-CSF treatment in the reduction of angio-
genic factors in the esophagus. In the human esophagus postir-
radiation and in a mouse model of esophageal overexpression
of IKKbca, GM-CSF has been indicated in esophageal
pro-angiogenic mechanisms (16, 37). Thus, the pleiotropic
factor GM-CSF may play multiple roles in EoE via direct
effects on other cells. Future studies will aid in determining the
potential impact of GM-CSF on the broad array of cells
involved in EoE, such as esophageal epithelial cells, endothelial
cells, resident and infiltrating esophageal antigen-presenting
cells, and their indirect effects on eosinophils.
In summary, the present study highlights an important role
for esophageal GM-CSF in regulating inflammatory patterns
in a mouse model of EoE. Esophageal GM-CSF is increased
in the context of eosinophilic inflammation, and these studies
support its involvement in esophageal eosinophilia, basal cell
hyperplasia, and vascular remodeling as potential therapeutic
targets for the treatment of EoE.
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